Advertisement
UK markets open in 3 hours 25 minutes
  • NIKKEI 225

    36,818.81
    -1,260.89 (-3.31%)
     
  • HANG SENG

    16,083.19
    -302.68 (-1.85%)
     
  • CRUDE OIL

    84.99
    +2.26 (+2.73%)
     
  • GOLD FUTURES

    2,402.20
    +4.20 (+0.18%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • Bitcoin GBP

    49,791.18
    -177.99 (-0.36%)
     
  • CMC Crypto 200

    1,274.92
    +389.38 (+42.23%)
     
  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     
  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     

Is Endo International a Great Stock for Value Investors?

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Endo International plc ENDP stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

ADVERTISEMENT

On this front, Endo International has a trailing twelve months PE ratio of 3, as you can see in the chart below:

This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 20.1x. If we focus on the long-term PE trend, Endo International’s current PE level puts it below its midpoint over the past five years, with the number having risen rapidly over the past few months.

Further, the stock’s PE also compares favorably with the broader industry’s trailing twelve months PE ratio, which stands at 76.7. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.

We should also point out that Endo International has a forward PE ratio (price relative to this year’s earnings) of just 4.1, which is tad higher than the current level. So it is fair to expect an increase in the company’s share price in the near term.

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.

Right now, Endo International has a P/S ratio of about 0.7. This is significantly lower than the S&P 500 average, which comes in at 3.3x right now. However, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.

If anything, ENDP is in the lower end of its range in the time period from a P/S metric, suggesting some level of undervalued trading—at least compared to historical norms.

Broad Value Outlook

In aggregate, Endo International currently has a Value Score of A, putting it into the top 20% of all stocks we cover from this look. This makes Endo International a solid choice for value investors.

What About the Stock Overall?

Though Endo International might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of B and a Momentum Score of D. This gives ENDP a Zacks VGM score — or its overarching fundamental grade — of A. (You can read more about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been downbeat. The current quarter has seen two estimates go higher in the past sixty days compared to seven lower, while the full year estimate has seen seven up and two down in the same time period.

This has had just a small impact on the consensus estimate though as the current quarter consensus estimate has decreased by 6.9% in the past two months, while the full year estimate has inched lower by 1.3%.:

Endo International plc Price and Consensus

 

Endo International plc Price and Consensus | Endo International plc Quote

The stock has just a Zacks Rank #3 (Hold) and we are looking for in-line performance from the company in the near term.

Bottom Line

Endo International is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Further, a strong industry rank (among Top 41% of more than 250 industries) instills our confidence.

However, with a Zacks Rank #3 it is hard to get too excited about this company overall. In fact, over the past two years, the broader industry has clearly underperformed the market at large, as you can see below:

So, value investors might want to wait for estimates and analyst sentiment to turn around in this name first, but once that happens, this stock could be a compelling pick.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.     

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.  

See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Endo International plc (ENDP) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research